Dietary Fructo-Oligosaccharides Dose-Dependently Modulate the Microbiome and Suppress Type 2 Lung Inflammation in a Murine Model of House Dust Mite-Induced Allergic Asthma

Why It Matters

The work demonstrates that precise prebiotic dosing can modulate gut‑lung immune axes, offering a potential non‑pharmacologic strategy to prevent or attenuate allergic asthma.

Key Takeaways

• FOS reduces lung Th2 cells dose‑dependently
• Higher FOS doses shift gut microbiome toward Prevotellaceae
• Serum acetate correlates with reduced type‑2 inflammation
• Eosinophil influx unchanged despite FOS supplementation
• 2.5‑5% FOS optimally increases cecal SCFAs

Pulse Analysis

The gut‑lung axis has emerged as a pivotal pathway through which dietary components influence respiratory health. Prebiotic fibers such as fructo‑oligosaccharides are fermented by intestinal microbes, producing short‑chain fatty acids (SCFAs) that act as signaling molecules for immune cells. In the context of allergic asthma, SCFAs can dampen type 2 cytokine production, enhance regulatory T‑cell function, and strengthen epithelial barriers, thereby reducing allergen‑driven inflammation. Understanding the dose‑response relationship of these fibers is essential for translating microbiome science into actionable nutrition guidance.

In murine models of house‑dust‑mite‑induced asthma, incremental FOS supplementation (1 %‑10 % w/w) produced a clear gradient of immunological effects. Although total eosinophil counts in bronchoalveolar lavage fluid remained stable, the proportion of Th2 cells in lung tissue fell markedly at 2.5 %, 5 %, and 10 % FOS, with the highest dose also lowering IL‑13 and CCL22 levels. Parallel gut analyses revealed dose‑specific shifts: 2.5 % FOS enriched Muribaculaceae, 5 % boosted Bacteroidaceae and Lachnospiraceae, and 10 % expanded Prevotellaceae while suppressing Lactobacillaceae. These microbial changes coincided with elevated cecal acetate, propionate, and butyrate, and serum acetate emerged as a strong inverse predictor of Th2 dominance, linking metabolic output to pulmonary immune modulation.

The implications for human health are twofold. First, precision nutrition—tailoring fiber type and concentration to individual microbiome profiles—could become a viable adjunct to conventional asthma therapies, potentially reducing reliance on inhaled corticosteroids. Second, the identified biomarkers, especially serum acetate and specific bacterial families, may serve as early indicators of therapeutic response. Future clinical trials should explore optimal FOS dosing in diverse populations, assess long‑term safety, and integrate metagenomic sequencing to personalize interventions. If successful, such strategies could shift asthma management toward preventive, diet‑based approaches that harness the body’s own microbial allies.